US biopharmaceutical company BridgeBio Pharma, Inc. (NASDAQ: BBIO), which develops medicines for genetic conditions, on Wednesday announced the release of new exploratory analyses from PROPEL 3, its global Phase 3 study of oral infigratinib in children with achondroplasia.
The findings indicate favourable trends beyond growth, including effects on sleep apnoea, otitis media and body composition.
After 52 weeks, mean total Apnoea-Hypopnea Index increased 10.4% from baseline in the oral infigratinib group, compared with a 49.2% rise for placebo; in children under eight, the measure was unchanged for oral infigratinib versus a 63.2% increase for placebo. The estimated annualised rate of otitis media events was 38% lower with oral infigratinib than placebo, and 47% lower in children under eight.
Previously published PROPEL 3 primary and secondary endpoint results reported a +2.10 cm/year improvement in annualised height velocity versus placebo (p
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease